| Name | Anumigilimab |
|---|
| Description | Anumigilimab (CSL-324) is an humanized IgG2a mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation[1][2]. |
|---|---|
| Related Catalog | |
| Target |
granulocyte colony-stimulating factor (G-CSF) receptor[1] |
| References |
| No Any Chemical & Physical Properties |